Semaglutide

Semaglutide is a highly stable, synthetic analogue of human glucagon-like peptide-1 (GLP-1). It has been structurally modified to resist degradation by the DPP-4 enzyme, dramatically extending its half-life to approximately 7 days and allowing for once-weekly administration.

It operates via a dual-action mechanism. Systemically, it dramatically slows gastric motility (the rate at which the stomach empties), resulting in prolonged physical satiety. Neurologically, it crosses the blood-brain barrier to bind with GLP-1 receptors in the hypothalamus, aggressively modulating hunger signals and reducing the compulsion for caloric intake.

In extensive clinical models, Semaglutide serves as the gold standard for metabolic regulation and obesity protocol research. Beyond simple appetite suppression, it effectively modulates insulin secretion in a glucose-dependent manner, heavily optimizing blood lipid profiles.

Test subjects adhering to a strict titration schedule typically observe a mean body weight reduction of up to 15% over 68 weeks. It is particularly noted for its high efficacy in targeting and reducing stubborn visceral adipose tissue.

A rigorous dose-escalation schedule (titration) is mandatory for Semaglutide to mitigate transient gastrointestinal side effects and allow physiological adaptation.

Semaglutide is dispatched from our Johannesburg laboratory as a lyophilized powder. It must be reconstituted prior to administration using Bacteriostatic Water (BAC). Extreme care must be taken to prevent molecular shearing during this process.

• Inject BAC water slowly against the side of the glass vial wall.
• Do not shake. Gently roll or swirl the vial until completely clear. Refrigerate immediately.